股票行情快报：蓝帆医疗（002382）2月27日主力资金净买入512.73万元

Core Viewpoint - Bluefan Medical (002382) has shown a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business performance [2]. Financial Performance - For the first three quarters of 2025, Bluefan Medical reported a main revenue of 4.182 billion yuan, a year-on-year decrease of 10.15% [2]. - The net profit attributable to shareholders was -286 million yuan, down 30.09% year-on-year [2]. - The net profit after deducting non-recurring items was -364 million yuan, reflecting a significant decline of 46.25% [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 1.401 billion yuan, a decrease of 15.02% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -151 million yuan, a drastic decline of 153.64% [2]. - The single-quarter net profit after deducting non-recurring items was -155 million yuan, down 151.16% year-on-year [2]. - The company's debt ratio stands at 41.01%, with investment income of 13.482 million yuan and financial expenses of 140 million yuan [2]. - The gross profit margin is reported at 13.66% [2]. Market Activity - As of February 27, 2026, Bluefan Medical's stock closed at 6.08 yuan, with an increase of 1.16% [1]. - The turnover rate was 1.14%, with a trading volume of 113,500 hands and a transaction amount of 68.9748 million yuan [1]. - On February 27, the net inflow of main funds was 5.1273 million yuan, accounting for 7.43% of the total transaction amount [1]. - The net inflow of speculative funds was 3.4474 million yuan, representing 5.0% of the total transaction amount [1]. - Retail investors experienced a net outflow of 8.5747 million yuan, which is 12.43% of the total transaction amount [1].